Adicet Bio (ACET) Q3 2026 earnings summary

Executive summary

• Q3 2026 net loss was $18.878 million versus $26.856 million YoY; nine-month net loss was $60.480 million versus $86.287 million.

• Prula-cel showed durable responses and a favorable safety profile in SLE; pivotal lupus nephritis (LN) study startup is underway.

• Cash, equivalents and short-term investments totaled $100.945 million at September 30, 2026; substantial doubt about funding operations for at least 12 months after statement issuance was identified.

Financial highlights

• Q3 operating expenses were $19.796 million versus $27.952 million YoY; nine-month expenses were $63.667 million versus $90.228 million.

• Q3 R&D expense was $15.6 million versus $22.9 million; nine-month R&D was $51.6 million, down 30%, primarily reflecting lower headcount and CRO costs.

• Q3 G&A expense was $4.2 million versus $5.1 million; nine-month G&A was $12.1 million, down 25%, mainly due to lower personnel costs and stock-based compensation.

• Net cash used in operations was $59.2 million for 9M 2026 versus $74.3 million; no product-sales revenue or Regeneron Agreement revenue was recorded in Q3 or 9M 2026.

Outlook and guidance

• The single-arm pivotal LN study is expected to enroll a double-digit number of patients, with complete renal response at 12 months as its primary endpoint.

• Q4 2026 FDA discussions will address potential pivotal development in lupus without nephritis; further prula-cel updates and 12-month follow-up data are expected in Q1 2027, with systemic sclerosis data in Q2 2027.

• ADI-212 mCRPC Phase 1 enrollment is anticipated in Q1 2027; the first in-vivo CAR-T clinical study is planned for H2 2027.

• Cash runway is expected into H2 2027 under the current plan, although management concluded available funding may not cover at least 12 months from issuance of the interim financial statements.